CSTL Castle Biosciences Inc
Price (delayed)
$18.76
Market cap
$534.92M
P/E Ratio
28.42
Dividend/share
N/A
EPS
$0.66
Enterprise value
$441.56M
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently
Highlights
CSTL's EPS has surged by 200% since the previous quarter and by 131% year-on-year
The net income has surged by 132% year-on-year
Castle Biosciences's quick ratio has increased by 18% YoY but it has decreased by 7% QoQ
The debt has soared by 72% YoY
Key stats
What are the main financial stats of CSTL
Market
Valuations
Earnings
Shares outstanding
28.51M
Market cap
$534.92M
Enterprise value
$441.56M
Price to earnings (P/E)
28.42
Price to book (P/B)
1.15
Price to sales (P/S)
1.57
EV/EBIT
19.94
EV/EBITDA
11.58
EV/Sales
1.33
Revenue
$332.07M
Gross profit
$271.86M
Operating income
$8.67M
Net income
$18.25M
EBIT
$22.14M
EBITDA
$38.14M
Free cash flow
$36.56M
Per share
Balance sheet
Liquidity
EPS
$0.66
EPS diluted
$0.62
Free cash flow per share
$1.32
Book value per share
$16.28
Revenue per share
$11.96
TBVPS
$15.3
Total assets
$531.24M
Total liabilities
$75.4M
Debt
$26.34M
Equity
$455.84M
Working capital
$310.76M
Debt to equity
0.06
Current ratio
7.29
Quick ratio
6.99
Net debt/EBITDA
-2.45
Margins
Efficiency
Dividend
EBITDA margin
11.5%
Gross margin
81.9%
Net margin
5.5%
Operating margin
2.6%
Return on assets
3.7%
Return on equity
4.2%
Return on invested capital
8%
Return on capital employed
4.6%
Return on sales
6.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSTL stock price
How has the Castle Biosciences stock price performed over time
Intraday
-4.43%
1 week
-8.89%
1 month
-32.05%
1 year
-5.54%
YTD
-29.61%
QTD
-29.61%
Financial performance
How have Castle Biosciences's revenue and profit performed over time
Revenue
$332.07M
Gross profit
$271.86M
Operating income
$8.67M
Net income
$18.25M
Gross margin
81.9%
Net margin
5.5%
The net margin has soared by 189% QoQ and by 121% YoY
The net income has surged by 132% year-on-year
The operating income has soared by 113% YoY
The operating margin has surged by 108% year-on-year
Growth
What is Castle Biosciences's growth rate over time
Valuation
What is Castle Biosciences stock price valuation
P/E
28.42
P/B
1.15
P/S
1.57
EV/EBIT
19.94
EV/EBITDA
11.58
EV/Sales
1.33
CSTL's EPS has surged by 200% since the previous quarter and by 131% year-on-year
CSTL's price to book (P/B) is 57% lower than its 5-year quarterly average of 2.7 and 28% lower than its last 4 quarters average of 1.6
The equity is up by 17% year-on-year and by 3.4% since the previous quarter
The P/S is 83% below the 5-year quarterly average of 9.1 and 32% below the last 4 quarters average of 2.3
CSTL's revenue has soared by 51% YoY and by 6% from the previous quarter
Efficiency
How efficient is Castle Biosciences business performance
Castle Biosciences's return on assets has surged by 185% QoQ and by 128% YoY
The ROE has soared by 180% QoQ and by 128% YoY
Castle Biosciences's return on invested capital has surged by 127% YoY and by 78% QoQ
CSTL's return on sales has surged by 126% year-on-year and by 81% since the previous quarter
Dividends
What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSTL.
Financial health
How did Castle Biosciences financials performed over time
The total liabilities has grown by 21% year-on-year and by 2.6% since the previous quarter
Castle Biosciences's quick ratio has increased by 18% YoY but it has decreased by 7% QoQ
The debt is 94% lower than the equity
The debt has soared by 72% YoY
CSTL's debt to equity has surged by 50% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.